Awiqli 700 IU Injection

Awiqli 700 IU Injection (Insulin Icodec 700 units/mL)

Awiqli 700 IU Injection contains Insulin Icodec 700 units/mL, a next-generation, ultra-long-acting basal insulin developed by Novo Nordisk. It is the world’s first approved once-weekly insulin designed to improve glycemic control in adults with type 2 diabetes mellitus, with approvals in certain regions extending to adults with type 1 diabetes mellitus when used alongside rapid-acting mealtime insulin.

Unlike traditional basal insulins that require daily administration, Awiqli is administered just once every week, reducing the number of annual basal insulin injections from approximately 365 to 52. This innovative dosing schedule may help improve treatment adherence and simplify diabetes management for eligible patients under healthcare professional supervision.

Awiqli works by providing a stable and sustained release of insulin over an entire week, helping maintain blood glucose levels within the target range. It belongs to the class of long-acting basal insulins and is supplied as a 700 units/mL (U-700) solution in a prefilled FlexTouch pen. The pen can deliver doses ranging from 10 to 700 units per injection, depending on individual treatment requirements.

Patients searching for Awiqli 700 IU Injection, Insulin Icodec Injection, weekly insulin shot, once-weekly basal insulin, Novo Nordisk diabetes medicine, or long-acting insulin for type 2 diabetes are referring to one of the most significant innovations in diabetes care in recent years. As the first commercially available weekly insulin, Awiqli represents a major advancement in simplifying insulin therapy while maintaining effective glycemic control.

In the United States, Awiqli received FDA approval in March 2026 as the first and only once-weekly basal insulin for adults with type 2 diabetes. It is also approved in the European Union, Australia, and several other international markets, with recent launches expanding access globally.

Purchase Awiqli 700 IU Injection (Insulin Icodec) from a trusted pharmaceutical supplier offering genuine diabetes medicines, competitive pricing, secure ordering, and worldwide shipping where permitted by local regulations. Prescription insulin products should only be used under the supervision of a qualified healthcare professional, with individualized dosing and regular blood glucose monitoring.

Frequently Asked Questions (FAQs)

What is Awiqli 700 IU Injection used for?

Awiqli is used to improve blood sugar control in adults with diabetes mellitus and is administered once weekly as a basal insulin.

What is the generic name of Awiqli?

The generic name of Awiqli is Insulin Icodec.

Is Awiqli the first once-weekly insulin?

Yes. Awiqli is the world’s first approved once-weekly basal insulin.

How often is Awiqli administered?

Awiqli is administered once every week, preferably on the same day each week.

How is Awiqli different from Lantus or Tresiba?

Awiqli is administered weekly, whereas Lantus (insulin glargine) and Tresiba (insulin degludec) are administered daily.

What are the common side effects of Awiqli?

Common side effects include hypoglycemia, injection-site reactions, weight gain, rash, and swelling of the hands or feet.